TLP
BEAM icon

Tri Locum Partners’s Beam Therapeutics BEAM Stock Holding History

Tri Locum Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-107,230
Closed -$3.28M – 66
2023
Q1 		$3.28M Buy
107,230
+25,212
+31% +$995K 1% 31
2022
Q4 		$3.21M Buy
82,018
+28,264
+53% +$1.27M 1.3% 28
2022
Q3 		$2.56M Buy
+53,754
New +$3.07M 0.7% 32

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tri Locum Partners's BEAM Position: Q2 2023 in Review

Tri Locum Partners sold out of Beam Therapeutics (BEAM) in Q2 2023, closing a stake of 107,230 shares — an estimated $3.28M sold.

Tri Locum Partners first reported a position in BEAM in Q3 2022 and held it in 3 quarters. The position peaked at $3.28M in Q1 2023. 193 funds tracked by Wall St. Rank hold BEAM as of Q2 2023.

  • Tri Locum Partners reported no remaining Beam Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Tri Locum Partners sold 107,230 Beam Therapeutics shares in Q2 2023, an estimated $3.28M.
  • Tri Locum Partners first reported a position in Beam Therapeutics in Q3 2022 and held it in 3 quarters.
  • Tri Locum Partners's Beam Therapeutics position peaked at $3.28M in Q1 2023.
  • 193 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2023.

Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.